Megakaryocyte development is a carefully controlled process that is at least partially regulated by cytokines. Previous investigations of megakaryocyte development have focused primarily on defining growth factors that induce or enhance differentiation. In this study we demonstrate that a specific cytokine. transforming growth factor 8 1 (TGFBl), inhibits the phorbol myristate acetate ( Growth factors such as IL-6, megakaryocyte stimulatory factor (MSF), thrombopoietic stimulatory factor (TSF), and megakaryocyte potentiator induce late murine and human megakaryocyte differentiation by enhancing platelet organelle and membrane development.'s2*5'8 At the stage between colony formation and cytoplasmic development, megakaryocytes become polyploid by endomitosis, a process of repeated nuclear replication without concomitant cell division that is unique to the megakaryocytic lineage. There are previous reports that transforming growth factor (31 (TGFB1) might also play a role in megakaryocytopoiesis. This is of particular interest because TGFPl is abundant in platelets and maturing megakaryocytes'-" and is released during platelet degran~lation.'*~~-'~ The TGFP family of polypeptides are multifunctional regulatory molecules that are synthesized by many different cells and for which nearly all cells have high-affinity receptors."." They have pleiotropic effects and inhibit proliferation of most cells, antagonize the mitogenic effects of some growth factors, and increase the expression of cell adhesion molecules and their receptor^.'^-'^ TGFBl, the predominant form, is a homodimeric, 25-Kd polypeptide that inhibits murine and human hematopoietic progenitor cell proliferation in the presence of IL-3 or granulocytemacrophage colony-stimulating factor in ~i t r o '~* '~.~~.~~ and in vivo.'' TGFPl can also inhibit megakaryocyte colony f~rmation.'~.'~ In K562 cells, TGFPl inhibits erythroid proliferation and enhances erythroid differentiation as measured by hemoglobin ~ynthesis.~' One approach to investigating the role of a growth factor like TGFBl in megakaryocytopoiesis would be to assess its effect on the differentiation of bone marrow megakaryocytes in short-term culture. However, such cultures contain other hematopoietic cells that could elaborate additional regula- tory factors. To date, the only pure megakaryocyte assay system is one in which single megakaryocytes are cultured in individual microtiter culture wells?6 However, with this system the limited number of cells precludes extensive analysis. Another approach would be to use megakaryocyte cell lines that respond to hematopoietic growth factors as a model of megakaryocyte development. We have previously established that the Dami cell line differentiates in response to phorbol myristate acetate (PMA) by becoming polyploid and increasing the expression of platelet membrane and granule constituents." In this study we examine the effects of purified human platelet TGFB1 on the differentiation of this cell line.
Growth factors such as IL-6, megakaryocyte stimulatory factor (MSF), thrombopoietic stimulatory factor (TSF), and megakaryocyte potentiator induce late murine and human megakaryocyte differentiation by enhancing platelet organelle and membrane development.'s2*5'8 At the stage between colony formation and cytoplasmic development, megakaryocytes become polyploid by endomitosis, a process of repeated nuclear replication without concomitant cell division that is unique to the megakaryocytic lineage. There are previous reports that transforming growth factor (31 (TGFB1) might also play a role in megakaryocytopoiesis. This is of particular interest because TGFPl is abundant in platelets and maturing megakaryocytes'-" and is released during platelet degran~lation.'*~~-'~ The TGFP family of polypeptides are multifunctional regulatory molecules that are synthesized by many different cells and for which nearly all cells have high-affinity receptors."." They have pleiotropic effects and inhibit proliferation of most cells, antagonize the mitogenic effects of some growth factors, and increase the expression of cell adhesion molecules and their receptor^.'^-'^ TGFBl, the predominant form, is a homodimeric, 25-Kd polypeptide that inhibits murine and human hematopoietic progenitor cell proliferation in the presence of IL-3 or granulocytemacrophage colony-stimulating factor in ~i t r o '~* '~.~~.~~ and in vivo.'' TGFPl can also inhibit megakaryocyte colony f~rmation.'~.'~ In K562 cells, TGFPl inhibits erythroid proliferation and enhances erythroid differentiation as measured by hemoglobin ~ynthesis.~' One approach to investigating the role of a growth factor like TGFBl in megakaryocytopoiesis would be to assess its effect on the differentiation of bone marrow megakaryocytes in short-term culture. However, such cultures contain other hematopoietic cells that could elaborate additional regula- tory factors. To date, the only pure megakaryocyte assay system is one in which single megakaryocytes are cultured in individual microtiter culture wells?6 However, with this system the limited number of cells precludes extensive analysis. Another approach would be to use megakaryocyte cell lines that respond to hematopoietic growth factors as a model of megakaryocyte development. We have previously established that the Dami cell line differentiates in response to phorbol myristate acetate (PMA) by becoming polyploid and increasing the expression of platelet membrane and granule constituents." In this study we examine the effects of purified human platelet TGFB1 on the differentiation of this cell line.
MATERIALS AND METHODS
Dami cells were cultured as previously described?' Briefly, cells were subcultured in Iscove's modified Dulbecco's medium (IMDM) containing 10% horse serum and 1% phytohemagglutinin-stimulated leukocyte-conditioned medium (PHA-LCM). 
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horse serum, 1% PHA-LCM, in IMDM as described for the Dami cells. Dami cells were seeded at 200,000 cells/mL and fed again after 2 days. Cells were harvested with trypsin 3 days later, and the nuclei were isolated, stained with propidium iodide, and analyzed on a Becton Dickinson FACS Analyzer (Mountain View, CA) as previously described." Freshly prepared lymphocytes and propidium iodide standard beads (Flow Cytometry Standards Corp, Research Triangle Park, NC) were used to mark the position of the 2N cells. Cells were considered to be polyploid or undergoing endomitosis if the DNA content was greater than 4N.
Total RNA was prepared by guanidine hydrochloride extraction and subject+ to electrophoresis in 1% agarose formaldehyde denaturing gels as previously described.** Equal amounts of total RNA (10 pg) from each sample underwent electrophoresis and were transferred electrophoretically to GeneScreen (New England Nuclear, Boston, MA). A 28-base pair oligonucleotide which contains a sequence from the middle of exon 6 of the human TGFj3l gene (R & D Systems), was labeled by kinase treatment of the 5' end, and used for hybridization. The filters were washed for 20 minutes twice with 6X SSC (1X SSC = 150 mmol/L sodium chloride, 1.0% sodium dodecyl sulfate, and 15 mmol/L sodium citrate) and twice in 4X SSC at rmm temperature, and exposed to Kcdak XAR film (Eastman Kodak, Rochester, NY) for autoradiography.
Analysis of ploidy.
Northern blot analysis.
RESULTS
The Dami cell line normally contains primarily 2N and 4N cells. In the presence of 5% human platelet-poor plasmaderived serum, PMA treatment for 5 days induces 30% to 40% of the Dami cells to increase their DNA content to greater than 4N. The induced cells fall into discrete ploidy groups containing 8N, 16N, and 32N complements of DNA." We found that the addition of between 1 and 5 ng/mL (40 and 200 pmol/L) TGFP1 completely inhibited PMA-induced endomitosis (Fig 1) . Concentrations of TGFPl ranging from 1 to 5 ng/mL (40 to 200 pmol/L) inhibited the PMA-induced endomitosis in a dose-dependent manner in the presence of the 5% plasma-derived serum. Half-maximal inhibition required 0.3 ng/mL (12 pmol/L) with the maximal inhibition at 1 to 5 ng/mL (40 to 200 pmol/L) (Fig 2) . In the presence of human serum, TGFPl was a more potent inhibitor of endomitosis. This may be due to secretion of TGFPl by platelets during serum preparation. Thus, in the presence of human serum, half-maximal inhibition was achieved at 0.16 ng/mL (6.4 pmol/L) TGFBl (Fig 2) . As shown in Fig 3, concentrations of TGFBI that inhibited endomitosis had no effect on the proliferation of control or PMA-treated Dami cells. A slight (18%) decrease in Dami cell proliferation at the higher TGFBl concentrations was noted in the control cells. When cell viability was assessed by trypan blue exclusion, the percentage of dead cells did not change over the entire range of TGFBl concentrations [ested (data not shown).
To determine the physiologic relevance of the TGFBImediated inhibition of endomitosis. the effect of TGFBl on normal human megakaryocytes in crJdc preparations of bone marrow cells was also analyzed. Normal human bone marrow was prepared by fractionation on Ficoll-Paque and cultured overnight to remove adherent cells. Preliminary experiments demonstrated that the only bone marrow cells which were capable of achieving a greater than 4N ploidy state were megakaryocytic by their positive reaction with anti-platelet GPlb and GPllb/llla monoclonal antibodies (MoAbs). The addition of IO ng/mL TGFBl (400 pmol/L) decreased the proportion of nucleated cells that spontaneously achieved a ploidy state greater than 4N during 5 days of culture from 2.50'16 to I .55% (Table I) . a 37% inhibition of baseline endomitosis in normal human megakaryocytes.
To determine whether the effects of TGFBl on endomitosis were reversible. Dami cells were cultured in the presence of PMA and TGFBl for 2 days followed by PMA alone for 3 days. The cells treated in this way became polyploid to the same extent as cells treated with PMA alone for 3 days ( Table 2 ). suggesting that the mechanism by which TGFB inhibits endomitosis is reversible. In cultures induced with PMA for 5 days, TGFBI treatment for the first 2 days resulted in a higher ploidy distribution than TGFBl treatment for the entire 5 days (Table 2 ). This suggests that the continuous presence of TGFBl is required for maximal inhibition. Decreasing the concentration of cells had noeffect on the extent of PMA-induced endomitosis or on the TGFBl inhibition (data not shown). To determine whether the Dami cells make TGFBl as has been demonstrated for normal megakaryocytes. total RNA was electrophoresed and transferred to filters for hybridization with a 28-nucleotide oligomer complementary to exon 6 of the human TGFBl gene. As shown in Fig 4. control and PMA-induced cells express the 2.2-kilobase TGFBl messenger RNA continuously with a slight increase in response to PMA. Incubation with an MoAb directed against TGFBl did not enhance the extent of endomitosis (data not shown).
DISCUSSION
Early megakaryocyte development is regulated by agents such as IL-3 that increase the proliferation of committed progenitor cells. As in other hematopoietic lineages. the proliferation of megakaryocyte progenitors in clonal assays is inhibited by TGFBl .1'.'6 Late megakaryocyte differentiation, including expression of platelet cytoplasmic membranes. granule. and stored components in polyploid megakaryacytes. is enhanced or induced by less well-defined growth factors like MSF. TSF. or IL-6.'.* TGFBl also inhibits this late stage of megakaryocyte maturation.'"" Positive regulatory factors that act on megakaryocytes at an intermediate stage of differentiation have not been clearly defined. Based on data derived from primary mixed-cell rat bone marrow cultures, it has been suggested that there may be an inhibitor of endomitosis; although to date no direct and clear regulation of human megakaryocyte endomitosis has been demonstrated in a purified cell system.".'0 In this report. we have demonstrated that purified human TGFBl inhibits develop . ment of the polyploid state of the human megakaryocytic Dami cell line and that this inhibitory effect does not require the presence of other hematopoietic cells. TGFPl similarly inhibited megakaryocyte endomitosis in primary cultures of normal human bone marrow that contained cells of other hematopoietic lineages.
Relatively high levels of TGFPl have been found in areas of active tissue differentiation that contain hematopoietic stem cells, such as bone marrow and fetal liver,-" and specifically in megakaryocytes.-'' As has been demonstrated in other cell lines with megakaryocytic TGFPl is expressed by the Dami cells. The level of expression is increased by PMA, an event that may be explained by the presence of three phorbol ester responsive elements (TREs) on the TGFPl gene.-'-' Incubation of Dami cells with a monoclonal TGFB 1 antibody at levels sufficient to neutralize 50 ng TGFPl did not enhance the extent of endomitosis, suggesting that it may not be released extracellularly, but this does not exclude the possibility of autocrine regulation.
It is well-known that TGFO1 inhibits DNA synthesis and proliferation of B cells, epithelial cells, and early bone marrow progenitor^.'^,'^ However, TGFPl did not affect Dami cell proliferation over the range of concentrations used to inhibit endomitosis. Thus, it appears that the mechanism of inhibition of endomitosis does not involve inhibition of DNA synthesis.
Of the four types of receptors for TGFP that have been identified, two are well-defined. The high affinity TGFP type I receptor is present on hematopoietic cells. It preferentially binds TGFBl and may be the principal cell surface molecule through which TGFPl induces its pleiotropic effects on signal transduction, altered gene expression, and changes in adhesion and growth control of hematopoietic cells.'-' The type I1 receptor is also a high affinity TGFPl receptor, and may also play a role in hematopoiesis.'-' It is possible that each receptor plays a specific role in mediating TGFPl action. Keller et a12* have suggested that if one of these were the principal receptor through which TGFPl mediates its effects on proliferation, loss of expression of this receptor might account for the loss of negative growth regulation in some leukemias. However, since we have shown that differentiation of the Dami cells, like that of normal megakaryocytes, is inhibited by TGFPl, it is possible that a different TGFP receptor may be involved in regulating megakaryocyte differentia tion.
In summary, we have described how the human megakaryocytic Dami cell line can be used as a tool to examine the regulation of megakaryocyte differentiation. Specifically, we have demonstrated that purified, exogenous TGFO1 directly inhibits endomitosis but not proliferation in a pure megakaryocyte cell system. Because platelets contain abundant amounts of TGFPl, this data supports the concept that megakaryocyte endomitosis may be regulated by a negative autocrine feedback mechanism.
